Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
Silence Therapeutics Plc - American Depository Share (SLN)
Company Research
Source: Business Wire
New divesiran data continue to show substantial reduction in phlebotomy frequency and lowering of hematocrit levels in PV patientsSilence also announces first subject dosed in Phase 2 study of divesiran in PV patientsCompany reinforces commitment to prioritize divesiran development as the first-in-class siRNA in PV LONDON--(BUSINESS WIRE)--Silence Therapeutics plc (“Silence” or the “Company”) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced additional results from the Phase 1 open label portion of the SANRECO study of divesiran, a siRNA targeting TMPRSS6, in patients with polycythemia vera (PV) were presented at the American Society of Hematology (ASH) Annual Meeting being held in San Diego, California.“Additional divesiran data presented at ASH continue to support a compelling profile in PV and highlight the broad potential of our siRNA platform to target both rare and common genetic diseases,” said Craig Toom
Show less
Read more
Impact Snapshot
Event Time:
SLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLN alerts
High impacting Silence Therapeutics Plc - American Depository Share news events
Weekly update
A roundup of the hottest topics
SLN
News
- Silence Therapeutics plc (SLN): Among the Oversold Global Stocks to Buy Right Now [Yahoo! Finance]Yahoo! Finance
- Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $55.00 price target on the stock.MarketBeat
- The Changing Market Dynamics of Immune Thrombocytopenia, Aplastic Anemia, and Diamond-Blackfan Anemia | DelveInsight InsightsPR Newswire
- The Changing Market Dynamics of Immune Thrombocytopenia, Aplastic Anemia, and Diamond-Blackfan Anemia | DelveInsight InsightsPR Newswire
- Silence Therapeutics plc (NASDAQ: SLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.MarketBeat
SLN
Sec Filings
- 12/20/24 - Form SCHEDULE
- 12/9/24 - Form 6-K
- 11/18/24 - Form 6-K
- SLN's page on the SEC website